NeOnc Technologies appoints Dr. Josh Neman as Chief Clinical Officer

NEONC TECHNOLOGIES HOLDINGS, INC.

Dr. Josh Neman, PhD, appointed CCO; formerly Associate Professor at USC Keck School and Scientific Director of USC Brain Tumor Center.
He will lead clinical strategy for four trials, including NEO100 approaching Phase 2a completion with full enrollment ahead of schedule.
Neman's research on tumor-neuron interactions and GABAergic signaling supports FDA approval path and AI/quantum computing integration.
Appointment aims to accelerate precision therapies for CNS cancers; NeOnc holds 176 patents worldwide.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.